Epilepsy, Reproductive Issues
Conditions
Keywords
anti-mullerian hormone, epilepsy, adolescent
Brief summary
The production of AMH starts in granulosa cells before birth and the levels within the serum decreases towards the menapouse. The levels of AMH do not change throughout the menstruation cycle hovewer, it can be affected in cases related to body mass index (BMI), polycyctic ovarian syndrome (PCOS). The lower levels of AMH had been documented after ovarian surgery, radiotheraphy and chemotheraphy. AMH is a member of Transforming Growth Faktor β (TGF- β ) and it has receptors in brain structures including hyppocammpus. It is highly active neurophysiologically and it has a protective effect against N-methyl-D -aspartate related neuronal injury that is demonstrated both in vivo and in vitro studies. As a result, being a neuroactive hormone; AMH may have an effect on seizures within epileptic patients or serum AMH levels may be effected in epileptic patients when compared with healthy ones.
Interventions
DIAGNOSTIC_TESTserum antimullerian hormone
serum antimullerian hormone will be analyzed for all participants
Sponsors
Near East University, Turkey
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
two groups (epileptic and healthy participants)
Eligibility
Sex/Gender
FEMALE
Age
12 Years to 18 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy and epileptic volunteer females * Ages between 12-18 * After menarche
Exclusion criteria
* ovarian surgery, * history of radiotherapy * history of chemotherapy, * before menarche
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| serum anti-mullerian hormone levels | baseline, at the time of examination | The comparison of serum levels of anti-mullerian hormone between epileptic and healthy groups |
Countries
Cyprus
Outcome results
None listed